<DOC>
	<DOCNO>NCT00262080</DOCNO>
	<brief_summary>The purpose study determine subcutaneous dose DX-88 ( ecallantide ; investigational product ) safe relieve symptom HAE patient suffer moderate severe acute attack HAE .</brief_summary>
	<brief_title>Efficacy Safety Study DX-88 Treat Acute Attacks Hereditary Angioedema ( HAE )</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<criteria>Age 10 older Documented diagnosis HAE , Type I II Executed informed consent Presentation treatment within 8 hour patient recognition moderate severe HAE attack Receipt investigational drug device , DX88 , within 30 day treatment Receipt noninvestigational C1INH ( C1 esterase inhibitor ) within 7 day treatment Diagnostic acquire angioedema , estrogendependent angioedema drug induce angioedema Pregnancy breastfeeding Patients receive DX88 within 7 day presentation dose Doubleblind Phase</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>